突变型JAK3磷酸化蛋白质组学分析预测JAK3抑制剂与MEK/BCL2抑制剂联合治疗T细胞急性淋巴细胞白血病的协同作用
本研究在转化Ba/F3淋巴细胞中描述JAK3(L857Q)/(M511I)激活突变下游的磷酸化蛋白质组,并用鲁索替尼或托法替尼急性抑制JAK1/JAK3后评估信号通路变化。磷酸化蛋白质组特征显示细胞周期、翻译起始、MAPK及PI3K/AKT信号、RNA代谢、表观遗传和凋亡过程通路显著改变。在携带JAK3突变的原代T-ALL样本中,司美替尼和曲美替尼(MEK)、布帕利西(PI3K)及ABT-199(BCL2)与JAK激酶抑制剂联合具有协同作用。
要点
- JAK3(L857Q)/(M511I)突变下游磷酸化蛋白质组涉及细胞周期、翻译起始、MAPK及PI3K/AKT等通路。
- 鲁索替尼或托法替尼抑制JAK1/JAK3后上述通路磷酸化显著改变。
- 在携带JAK3突变的原代T-ALL样本中,MEK、PI3K及BCL2抑制剂与JAK抑制剂联合具有协同作用。
核心结论
- 本研究首次详细描述JAK3突变调控的下游信号通路分子特征,有助于理解组成性激酶激活驱动的致癌过程并改进联合治疗方案。
研究设计与样本
- 在转化Ba/F3淋巴细胞中描述JAK3(L857Q)/(M511I)激活突变下游的磷酸化蛋白质组。
- 使用JAK激酶抑制剂鲁索替尼或托法替尼急性抑制JAK1/JAK3后评估JAK3突变调控的信号通路。
- 在携带JAK3突变的原代T-ALL样本中,将司美替尼和曲美替尼(MEK)、布帕利西(PI3K)及ABT-199(BCL2)与JAK激酶抑制剂联合测试协同作用。
主要发现
- 磷酸化蛋白质组特征显示细胞周期、翻译起始、丝裂原活化蛋白激酶及磷脂酰肌醇-4,5-二磷酸3-激酶(PI3K)/AKT信号、RNA代谢以及表观遗传和凋亡过程通路显著改变。
- 在携带JAK3突变的原代T-ALL样本中,司美替尼和曲美替尼(MEK)、布帕利西(PI3K)及ABT-199(BCL2)与JAK激酶抑制剂联合具有协同作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutations in the interleukin-7 receptor (IL7R) or the Janus kinase 3 (JAK3) kinase occur frequently in T-cell acute lymphoblastic leukemia (T-ALL) and both are able to drive cellular transformation and the development of T-ALL in mouse models. However, the signal transduction pathways downstream of JAK3 mutations remain poorly characterized. Here we describe the phosphoproteome downstream of the JAK3(L857Q)/(M511I) activating mutations in transformed Ba/F3 lymphocyte cells. Signaling pathways regulated by JAK3 mutants were assessed following acute inhibition of JAK1/JAK3 using the JAK kinase inhibitors ruxolitinib or tofacitinib. Comprehensive network interrogation using the phosphoproteomic signatures identified significant changes in pathways regulating cell cycle, translation initiation, mitogen-activated protein kinase and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signaling, RNA metabolism, as well as epigenetic and apoptotic processes. Key regulatory proteins within pathways that showed altered phosphorylation following JAK inhibition were targeted using selumetinib and trametinib (MEK), buparlisib (PI3K) and ABT-199 (BCL2), and found to be synergistic in combination with JAK kinase inhibitors in primary T-ALL samples harboring JAK3 mutations. These data provide the first detailed molecular characterization of the downstream signaling pathways regulated by JAK3 mutations and provide further understanding into the oncogenic processes regulated by constitutive kinase activation aiding in the development of improved combinatorial treatment regimens.
引用
- Degryse S, de Bock CE, Demeyer S, et al. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2017. PMID: 28852199. doi:10.1038/leu.2017.276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。